LucIDix Platform™ – Fail-Safe, Logic-Gated Biotherapeutic Computers for Autonomous Precision Medicine
Fuente:
Zenodo
Guardado en:
| Autor principal: | |
|---|---|
| Formato: | Recurso digital |
| Publicado: |
Zenodo
2025
|
| Acceso en línea: | |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| _version_ | 1866902288817192960 |
|---|---|
| author | Taheri Kal-Koshvandi, Afsaneh |
| author_facet | Taheri Kal-Koshvandi, Afsaneh |
| contents | <p>LucIDix is a <strong>revolutionary bio-circuit platform</strong> creating <em>self-driving cellular therapeutics</em>. By integrating patented light-free bioluminescence (BRET), CRISPR logic gates, and AI-driven feedback loops, our technology enables real-time disease detection, decision-making, and treatment <em>within living tissues</em>—eliminating external hardware, toxic co-factors, and manual intervention. With <strong>8+ patent families</strong> securing core IP, LucIDix targets a $175B precision medicine market through modular applications in oncology, neurology, and regenerative therapies.</p> <p> </p> <p><em>"A.T.K is Founder/CEO of Lucidix Inc. and holds equity. All patents are assigned to Lucidix Inc."</em></p> <p> </p> <p> </p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_16447749 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | LucIDix Platform™ – Fail-Safe, Logic-Gated Biotherapeutic Computers for Autonomous Precision Medicine Taheri Kal-Koshvandi, Afsaneh <p>LucIDix is a <strong>revolutionary bio-circuit platform</strong> creating <em>self-driving cellular therapeutics</em>. By integrating patented light-free bioluminescence (BRET), CRISPR logic gates, and AI-driven feedback loops, our technology enables real-time disease detection, decision-making, and treatment <em>within living tissues</em>—eliminating external hardware, toxic co-factors, and manual intervention. With <strong>8+ patent families</strong> securing core IP, LucIDix targets a $175B precision medicine market through modular applications in oncology, neurology, and regenerative therapies.</p> <p> </p> <p><em>"A.T.K is Founder/CEO of Lucidix Inc. and holds equity. All patents are assigned to Lucidix Inc."</em></p> <p> </p> <p> </p> |
| title | LucIDix Platform™ – Fail-Safe, Logic-Gated Biotherapeutic Computers for Autonomous Precision Medicine |
| url | https://doi.org/10.5281/zenodo.16447749 |